Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0CNJHC)
| ADC Name |
JK06
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
JK06; SAL006
Click to Show/Hide
|
|||||
| Organization |
Salubris Pharmaceuticals (Originator)
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-5T4 antibody
|
Antibody Info | ||||
| Antigen Name |
Trophoblast glycoprotein (TPBG)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
vedotin
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Key eligibility: Adults (≥18) with advanced/metastatic solid tumors (ECOG ≤1, measurable disease per RECIST 1.1). Major exclusions: active/unstable CNS metastases, recent major surgery (6 weeks), cardiovascular events (6 months), grade ≥2 neuropathy, live vaccinations (4 weeks), or hypersensitivity to JK06 components. Requires archival tumor samples and acceptable organ function (ANC ≥1,500/uL, platelets ≥100,000, bilirubin ≤1.5×ULN).
Click to Show/Hide
|
||||
| Administration Dosage |
Escalating repeated doses of JK06 administered intravenously. A cycle of treatment is defined as 21 days.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06667960 | Clinical Status | PHASE1|||PHASE2 | ||
| Clinical Description | A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK06, a 5T4 Antibody Drug Conjugate, in Patients with Unresectable Locally Advanced or Metastatic Cancer | ||||
| Primary Endpoint |
Primary objectives assess safety through DLT incidence (first 21 days), MTD/RP2D determination (up to 14 months), and treatment-emergent AE/SAE monitoring (treatment period through 28 days post-last dose) in advanced solid tumor patients receiving JK06.
|
||||
| Other Endpoint |
Secondary endpoints evaluate PK parameters (Cmax, AUC), immunogenicity (ADA levels), and efficacy measures (ORR/DCR by RECIST v1.1, PFS) through 104 weeks of treatment follow-up.
|
||||